SG11201607029QA - Anti-cd38 antibodies for treatment of acute lymphoblastic leukemia - Google Patents

Anti-cd38 antibodies for treatment of acute lymphoblastic leukemia

Info

Publication number
SG11201607029QA
SG11201607029QA SG11201607029QA SG11201607029QA SG11201607029QA SG 11201607029Q A SG11201607029Q A SG 11201607029QA SG 11201607029Q A SG11201607029Q A SG 11201607029QA SG 11201607029Q A SG11201607029Q A SG 11201607029QA SG 11201607029Q A SG11201607029Q A SG 11201607029QA
Authority
SG
Singapore
Prior art keywords
antibodies
treatment
lymphoblastic leukemia
acute lymphoblastic
leukemia
Prior art date
Application number
SG11201607029QA
Inventor
Parul Doshi
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54006455&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201607029Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of SG11201607029QA publication Critical patent/SG11201607029QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201607029QA 2014-02-28 2015-02-25 Anti-cd38 antibodies for treatment of acute lymphoblastic leukemia SG11201607029QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461946008P 2014-02-28 2014-02-28
US201462004540P 2014-05-29 2014-05-29
PCT/US2015/017425 WO2015130732A2 (en) 2014-02-28 2015-02-25 Anti-cd38 antibodies for treatment of acute lymphoblastic leukemia

Publications (1)

Publication Number Publication Date
SG11201607029QA true SG11201607029QA (en) 2016-09-29

Family

ID=54006455

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201607029QA SG11201607029QA (en) 2014-02-28 2015-02-25 Anti-cd38 antibodies for treatment of acute lymphoblastic leukemia

Country Status (30)

Country Link
US (3) US9732154B2 (en)
EP (2) EP4272738A3 (en)
JP (1) JP6543262B2 (en)
KR (2) KR102588587B1 (en)
CN (1) CN106456731B (en)
AU (3) AU2015223209A1 (en)
BR (1) BR112016019871A2 (en)
CA (1) CA2940865C (en)
CL (1) CL2016002157A1 (en)
CR (1) CR20160387A (en)
DK (1) DK3110440T5 (en)
DO (1) DOP2016000225A (en)
EA (1) EA037597B1 (en)
ES (1) ES2959504T3 (en)
FI (1) FI3110440T3 (en)
GT (1) GT201600171A (en)
HR (1) HRP20231021T1 (en)
HU (1) HUE063044T2 (en)
IL (1) IL247403B (en)
LT (1) LT3110440T (en)
MX (2) MX388464B (en)
MY (1) MY176517A (en)
PE (1) PE20161389A1 (en)
PH (1) PH12016501672A1 (en)
SG (1) SG11201607029QA (en)
SI (1) SI3110440T1 (en)
SV (1) SV2016005266A (en)
UA (1) UA122961C2 (en)
WO (1) WO2015130732A2 (en)
ZA (2) ZA201606683B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
ES2890669T3 (en) 2014-09-09 2022-01-21 Janssen Biotech Inc Combination therapies with anti-CD38 antibodies
SG11201704390PA (en) 2014-12-04 2017-06-29 Janssen Biotech Inc Anti-cd38 antibodies for treatment of acute myeloid leukemia
KR102602754B1 (en) 2015-05-20 2023-11-14 얀센 바이오테크 인코포레이티드 Anti-CD38 antibodies for treating light chain amyloidosis and other CD38-positive hematological malignancies
CN107708734B (en) 2015-06-22 2022-01-11 詹森生物科技公司 Combination therapy of heme malignancies with anti-CD 38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
CA2998611A1 (en) * 2015-09-14 2017-03-23 Leukemia Therapeutics, LLC Identification of novel diagnostics and therapeutics by modulating rhoh
ES2862425T3 (en) 2015-11-03 2021-10-07 Janssen Biotech Inc Subcutaneous formulations of anti-CD38 antibodies and their uses
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
JP7679196B2 (en) * 2017-06-08 2025-05-19 ブラック ベルト セラピューティクス リミテッド CD38 regulatory antibody
US20200121815A1 (en) * 2017-07-31 2020-04-23 Actinium Pharmaceuticals, Inc. Treatments for a hematological malignancy
CN107245529A (en) * 2017-08-08 2017-10-13 杭州千麦医学检验所有限公司 Blood disease fusion screening method
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Multispecific molecules that bind to bcma and uses thereof
EP3668896A1 (en) * 2017-08-16 2020-06-24 Black Belt Therapeutics Limited Cd38 modulating antibody
MA50514A (en) 2017-10-31 2020-09-09 Janssen Biotech Inc HIGH-RISK MULTIPLE MYELOMA TREATMENT METHODS
KR20210011002A (en) 2018-05-16 2021-01-29 얀센 바이오테크 인코포레이티드 Methods of treating cancer and methods of improving the efficacy of T-cell reinduction therapeutics
CA3115660A1 (en) 2018-10-12 2020-04-16 Hassan JUMAA-WEINACHT Monoclonal antibody composition for treatment of philadelphia chromosome positive acute lymphoblastic leukemia
TWI820270B (en) * 2018-12-14 2023-11-01 德商莫菲西斯公司 Antibody formulations
WO2020170211A1 (en) * 2019-02-22 2020-08-27 Janssen Biotech, Inc. Methods of treating newly diagnosed multiple myeloma with a combination of an antibody that specifically binds cd38, lenalidomide and dexamethasone
EP3935087A4 (en) * 2019-03-08 2022-12-07 Cedars-Sinai Medical Center ANTI-CD38 AGENTS FOR DESENSITIZATION AND TREATMENT OF ANTIBODY MEDIATED REJECTION OF ORGAN TRANSPLANTS
CN114616245B (en) * 2019-12-13 2024-02-23 山东先声生物制药有限公司 anti-CD 38 antibody and application thereof
WO2021259227A1 (en) * 2020-06-23 2021-12-30 江苏康缘药业股份有限公司 Anti-cd38 antibody and use thereof
US20240109977A1 (en) 2021-01-14 2024-04-04 Morphosys Ag Anti-cd38 antibodies and their uses
US20220275090A1 (en) * 2021-02-22 2022-09-01 Janssen Biotech, Inc. Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
TW202302642A (en) 2021-03-01 2023-01-16 德商莫菲西斯公司 Anti-cd38 antibodies for use in the treatment of antibody-mediated transplant rejection
WO2025153973A1 (en) 2024-01-16 2025-07-24 MorphoSys GmbH Highly concentrated liquid formulations for antibodies

Family Cites Families (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE3785186T2 (en) 1986-09-02 1993-07-15 Enzon Lab Inc BINDING MOLECULE WITH SINGLE POLYPEPTIDE CHAIN.
HUT53672A (en) 1988-02-25 1990-11-28 Gen Hospital Corp Quick immunoselective cloning process
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2087272C (en) 1990-07-13 2005-10-11 Brian Seed Cd53 cell surface antigen and use thereof
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
AU690528B2 (en) 1992-12-04 1998-04-30 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
WO1994017184A1 (en) 1993-01-29 1994-08-04 Schering Corporation Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
WO1998016245A1 (en) 1996-10-15 1998-04-23 Shionogi & Co., Ltd. Method of autoantibody assay
US6083477A (en) 1996-10-17 2000-07-04 Immunomedics, Inc. Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
WO2000006194A2 (en) 1997-02-05 2000-02-10 Biotransplant, Inc. Depletion of cells responsible for antibody-mediated graft rejection
AU745823B2 (en) 1997-05-02 2002-04-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Immunotoxins, comprising an onc protein, directed against malignant cells
AU770718B2 (en) 1998-06-05 2004-02-26 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to CD38 to treat multiple myeloma
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
HUP0104865A3 (en) * 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
CN100436425C (en) 2000-02-15 2008-11-26 安斯泰来制药有限公司 Fused imidazolium derivatives
FR2807767B1 (en) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement MONOCLONAL ANTIBODIES ANTI-D
JP2003535908A (en) 2000-06-22 2003-12-02 アイデック ファーマスーティカルズ コーポレイション Bispecific fusion proteins and methods of use to enhance effector cells that kill target cells
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
JP4139214B2 (en) 2000-10-17 2008-08-27 トリュデュ インスティチュート，インク． Chemotaxis regulated by CD38
US20070042436A1 (en) 2000-10-17 2007-02-22 Lund Frances E CD38 modulated chemotaxis
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US20040166490A1 (en) 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
AU2003257419B2 (en) 2002-06-13 2010-02-25 Crucell Holland, B.V. OX40 (CD134) receptor agonistic and therapeutic use
CN1942588B (en) 2003-03-05 2013-06-12 海洋酶公司 Soluble hyaluronidase glycoproteins (sHASEGP), methods for their preparation, their use and pharmaceutical compositions comprising them
WO2004092160A1 (en) 2003-04-15 2004-10-28 Astellas Pharma Inc. Bromide and its crystal
RS20150135A1 (en) 2003-05-30 2015-08-31 Genentech Inc. Treatment with anti-vegf antibodies
WO2004111233A1 (en) 2003-06-11 2004-12-23 Chugai Seiyaku Kabushiki Kaisha Process for producing antibody
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
CA2542840A1 (en) 2003-10-22 2005-05-12 University Of Rochester Anti-thymocyte antiserum and use thereof to trigger b cell apoptosis
WO2005044855A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
JP4712724B2 (en) 2003-12-23 2011-06-29 クルセル ホランド ベー ヴェー Human binding molecule for CD1a
MXPA06008700A (en) 2004-02-06 2007-01-19 Morphosys Ag Anti-cd38 human antibodies and uses therefor.
RS54056B1 (en) 2004-02-06 2015-10-30 Morphosys Ag Anti-cd38 human antibodies and uses therefor
PT103245A (en) 2005-03-14 2005-09-30 Abreu Alfredo Ferreira De Cutter head for e.g. planning medium-density timber, has fast knife replacement system consisting of magnet tool acting directly upon knives to allow insertion or removal of knives in space open by lever tool
SG10201912554TA (en) * 2005-03-23 2020-02-27 Genmab As Antibodies against cd38 for treatment of multiple myeloma
WO2006106905A1 (en) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
CA3151350A1 (en) 2005-05-09 2006-11-16 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
EP1888647A2 (en) 2005-05-24 2008-02-20 MorphoSys AG Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38
DK2860192T3 (en) 2005-10-12 2018-01-02 Morphosys Ag Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38
WO2007075326A2 (en) 2005-12-09 2007-07-05 Seattle Genetics, Inc. Methods of using cd40 binding agents
EP1999154B1 (en) 2006-03-24 2012-10-24 Merck Patent GmbH Engineered heterodimeric protein domains
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
EP3025712A1 (en) 2006-08-02 2016-06-01 Sunesis Pharmaceuticals, Inc. Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid and cytarabine (ara-c) for the treatment of leukemia
WO2008073160A2 (en) 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Methods for converting or inducing protective immunity
EP3753576A1 (en) 2006-09-26 2020-12-23 Genmab A/S Combination treatment of cd38-expressing tumors
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
US7618992B2 (en) 2006-12-29 2009-11-17 Astellas Pharma Inc. Method of treating cancer by co-administration of anticancer agents
CA2681743A1 (en) 2007-03-22 2008-09-25 Imclone Llc Stable antibody formulations
ES2667863T3 (en) 2007-03-29 2018-05-14 Genmab A/S Bispecific antibodies and their production methods
AU2008232903B9 (en) 2007-03-30 2013-09-05 Medimmune Llc Antibodies with decreased deamidation profiles
AU2008260445A1 (en) 2007-06-01 2008-12-11 Biogen Idec Ma Inc. Cripto binding molecules
CN102131828B (en) 2007-06-18 2015-06-17 默沙东有限责任公司 Antibody against human programmed death receptor PD-1
US20090076249A1 (en) 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
CA2705263A1 (en) 2007-11-09 2009-05-14 Novartis Ag Combination therapy with an antagonist anti-cd 40 antibody and cyclophosphamide, doxorubicin, vincristine and prednisone (chop) for treatment of b-cell malignancies
US8440199B2 (en) 2007-12-12 2013-05-14 Imperial Innovations Limited Methods for mobilizing mesenchymal stem cells in a patient
WO2009085462A1 (en) 2007-12-19 2009-07-09 Centocor, Inc. Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
PL2235064T3 (en) 2008-01-07 2016-06-30 Amgen Inc Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
JP2011517320A (en) 2008-03-03 2011-06-02 ダイアックス コーポレーション Metalloprotease 9 binding protein and metalloprotease 2 binding protein
CN101970650B (en) 2008-03-06 2017-07-25 哈洛齐梅公司 Large-scale production of soluble hyaluronidase
TWI532498B (en) 2008-03-17 2016-05-11 巴克斯特保健公司 Combination and method for subcutaneous administration of immunoglobulin and hyaluronic acid
AU2009228616B2 (en) 2008-03-25 2014-07-24 Roche Glycart Ag Use of a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-Hodgkin' s lymphomas
SG187427A1 (en) 2008-04-14 2013-02-28 Halozyme Inc Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
TWI394580B (en) 2008-04-28 2013-05-01 Halozyme Inc Super fast-acting insulin compositions
CA2722466A1 (en) 2008-04-29 2009-11-05 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
SMT201900278T1 (en) * 2008-11-07 2019-07-11 Amgen Res Munich Gmbh Treatment of acute lymphoblastic leukemia
EP2191841A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
SMT202000092T1 (en) 2009-05-14 2020-05-08 Ambit Biosciences Corp Spray dried formulation of ac220
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
CA2774053C (en) 2009-09-17 2015-04-28 Baxter Healthcare, S.A. Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
DK2486141T3 (en) 2009-10-07 2018-04-23 Macrogenics Inc FC-REGION-CONTAINING POLYPEPTIDES THAT PROVIDE IMPROVED EFFECTOR FUNCTION BASED ON CHANGES OF THE SCOPE OF FUCOSYLATION AND PROCEDURES FOR THEIR USE
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
SG184355A1 (en) 2010-03-01 2012-11-29 Progenics Pharm Inc Concentrated protein formulations and uses thereof
GB201003701D0 (en) 2010-03-05 2010-04-21 Cilian Ag System for the expression of a protein
WO2011121588A1 (en) 2010-03-29 2011-10-06 Ben Gurion University Of The Negev Research And Development Authority Method and system for detecting and monitoring hematological cancer
KR101930964B1 (en) 2010-04-20 2018-12-19 젠맵 에이/에스 Heterodimeric antibody fc-containing proteins and methods for production thereof
CA2797981C (en) 2010-05-14 2019-04-23 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
DK2580243T3 (en) 2010-06-09 2020-01-13 Genmab As ANTIBODIES AGAINST HUMAN CD38
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
NZ607473A (en) 2010-09-27 2014-11-28 Morphosys Ag Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl
KR101973930B1 (en) 2010-11-05 2019-04-29 자임워크스 인코포레이티드 Stable heterodimeric antibody design with mutations in the fc domain
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
UA112170C2 (en) 2010-12-10 2016-08-10 Санофі ANTI-TUMOR COMBINATION CONTAINING AN ANTIBODY SPECIFICALLY RECOGNIZING CD38 AND BORTESOMB
CL2013001944A1 (en) 2010-12-30 2014-09-12 Takeda Pharmaceutical Isolated antibody that specifically binds to human cd38 and cinomolgo cd38; nucleic acid encoding it; host cell; Method of production; and its use to treat an autoimmune disease.
JOP20210044A1 (en) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co Anti-CD38 . antibody
EP2688887B1 (en) 2011-03-23 2015-05-13 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
AR085934A1 (en) 2011-04-08 2013-11-06 Ab Science MULTIPLE MYELOMA TREATMENT WITH MASITINIB
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
EP2561868A1 (en) 2011-08-24 2013-02-27 Anton Bernhard Van Oosten Pharmaceutical compositions comprising hydroxychloroquine (HCQ), Curcumin, Piperine/BioPerine and uses thereof in the medical field
WO2013028186A1 (en) 2011-08-24 2013-02-28 Oxford Oncology Inc. Low-dose combination chemotherapy
MX360741B (en) 2011-10-28 2018-11-14 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof.
WO2013083140A1 (en) 2011-12-07 2013-06-13 N.V. Nutricia Beta-lactoglobulin peptides for treating cow's milk protein allergy
SMT201900630T1 (en) 2011-12-30 2020-01-14 Halozyme Inc Ph20 polypeptide variants, formulations and uses thereof
CN104159614A (en) 2012-03-07 2014-11-19 卡迪拉保健有限公司 Pharmaceutical formulations of TNF-alpha antibodies
KR101809858B1 (en) 2012-04-04 2017-12-15 할로자임, 아이엔씨 Combination therapy with an anti-hyaluronan agent and a tumor-targeted taxane
JP6448533B2 (en) 2012-05-15 2019-01-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Cancer immunotherapy by disrupting PD-1 / PD-L1 signaling
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
JP6426093B2 (en) 2012-09-25 2018-11-28 モルフォシス・アーゲー Combination and use
US9486547B2 (en) 2012-11-05 2016-11-08 Morphosys Ag Radiolabelled antibody and uses thereof
UA118255C2 (en) 2012-12-07 2018-12-26 Санофі Compositions comprising anti-cd38 antibodies and lenalidomide
CN105188749B (en) 2012-12-21 2017-12-19 西雅图基因公司 Anti-NTB-A antibodies and related compositions and methods
WO2014142220A1 (en) 2013-03-13 2014-09-18 アステラス製薬株式会社 Anti-tumor agent
US20140271644A1 (en) * 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Combination/adjuvant therapy for wt-1-positive disease
PT2992013T (en) 2013-04-29 2020-03-05 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
US20140356318A1 (en) 2013-05-28 2014-12-04 Israel Barken Adoptive cell therapy with specific regulatory lymphocytes
US20160235842A1 (en) 2013-07-15 2016-08-18 The Board Of Trustees Of The Leland Stanford Junior University Medical uses of cd38 agonists
WO2015067570A2 (en) 2013-11-06 2015-05-14 Boehringer Ingelheim International Gmbh Pharmaceutical combinations comprising cd33 antibodies and de-methylating agents
ES2711498T3 (en) 2014-02-14 2019-05-06 Cellectis Immunotherapy cells designed by genetic engineering to direct an antigen present in immune cells and pathological cells
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
WO2015195555A1 (en) 2014-06-16 2015-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells
EP3154581B1 (en) 2014-06-16 2019-02-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Blocking cd38 using anti-cd38 f(ab')2 to protect nk cells
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
MA39070A1 (en) 2014-07-31 2017-11-30 Sanofi Sa Anti-cd38 antibodies specific for the treatment of human cancers
ES2890669T3 (en) 2014-09-09 2022-01-21 Janssen Biotech Inc Combination therapies with anti-CD38 antibodies
SG11201704390PA (en) 2014-12-04 2017-06-29 Janssen Biotech Inc Anti-cd38 antibodies for treatment of acute myeloid leukemia
MA41555A (en) 2015-02-17 2017-12-26 Millennium Pharm Inc POLYTHERAPY FOR CANCER TREATMENT
KR102602754B1 (en) 2015-05-20 2023-11-14 얀센 바이오테크 인코포레이티드 Anti-CD38 antibodies for treating light chain amyloidosis and other CD38-positive hematological malignancies
CN107708734B (en) 2015-06-22 2022-01-11 詹森生物科技公司 Combination therapy of heme malignancies with anti-CD 38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
SMT202400127T1 (en) 2015-06-24 2024-05-14 Janssen Biotech Inc Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
CN107921050A (en) 2015-06-29 2018-04-17 阿布拉科斯生物科学有限公司 Use the method for nano particle MTOR inhibitor conjoint therapy treatment haematological malignancies
ES2862425T3 (en) 2015-11-03 2021-10-07 Janssen Biotech Inc Subcutaneous formulations of anti-CD38 antibodies and their uses
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
US20170121417A1 (en) 2015-11-03 2017-05-04 Janssen Biotech, Inc. Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses
JP2019527678A (en) 2016-06-28 2019-10-03 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー Treatment of IgE-mediated diseases with antibodies that specifically bind to CD38
US20180117150A1 (en) 2016-11-01 2018-05-03 Janssen Biotech, Inc. Combination Therapies for CD38-Positive Hematological Malignances with ANTI-CD38 Antibodies and Cyclophosphamide
MA50514A (en) 2017-10-31 2020-09-09 Janssen Biotech Inc HIGH-RISK MULTIPLE MYELOMA TREATMENT METHODS
MX2020010144A (en) 2018-03-28 2020-12-07 Takeda Pharmaceuticals Co Subcutaneous dosing of anti-cd38 antibodies.
US20190298827A1 (en) 2018-04-03 2019-10-03 Janssen Biotech, Inc. Methods of Treating Multiple Myeloma
KR20210011002A (en) 2018-05-16 2021-01-29 얀센 바이오테크 인코포레이티드 Methods of treating cancer and methods of improving the efficacy of T-cell reinduction therapeutics
EP3867275A2 (en) 2018-10-17 2021-08-25 Janssen Biotech, Inc. Method of providing subcutaneous administration of anti-cd38 antibodies
EA202191352A1 (en) 2018-11-13 2021-08-11 Янссен Байотек, Инк. CONTROL OF THE CONTENT OF MICROELEMENTS-METALS DURING THE PRODUCTION OF ANTIBODIES TO CD38
WO2020170211A1 (en) 2019-02-22 2020-08-27 Janssen Biotech, Inc. Methods of treating newly diagnosed multiple myeloma with a combination of an antibody that specifically binds cd38, lenalidomide and dexamethasone
WO2020194243A1 (en) 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with lenalidomide and dexamethasone
US20200316197A1 (en) 2019-03-28 2020-10-08 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone
US20200308297A1 (en) 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses
US20200308296A1 (en) 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone
US20200330593A1 (en) 2019-03-28 2020-10-22 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib, Mephalan and Prednisone
US20200397896A1 (en) 2019-04-19 2020-12-24 Janssen Biotech, Inc. Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
US20200405854A1 (en) 2019-04-19 2020-12-31 Janssen Biotech, Inc. Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
US20200392242A1 (en) 2019-04-19 2020-12-17 Janssen Biotech, Inc. Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
US20220275090A1 (en) 2021-02-22 2022-09-01 Janssen Biotech, Inc. Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors

Also Published As

Publication number Publication date
JP2017507954A (en) 2017-03-23
ZA201606683B (en) 2020-03-25
US20150246975A1 (en) 2015-09-03
EP3110440A2 (en) 2017-01-04
EP3110440B9 (en) 2024-01-24
ZA201708448B (en) 2019-05-29
MY176517A (en) 2020-08-13
CL2016002157A1 (en) 2017-07-28
IL247403B (en) 2021-12-01
UA122961C2 (en) 2021-01-27
EA037597B1 (en) 2021-04-20
BR112016019871A2 (en) 2017-10-17
AU2015223209A1 (en) 2016-09-08
CN106456731A (en) 2017-02-22
JP6543262B2 (en) 2019-07-10
KR20220119191A (en) 2022-08-26
HUE063044T2 (en) 2023-12-28
EA201691748A1 (en) 2016-12-30
PE20161389A1 (en) 2016-12-28
EP3110440B1 (en) 2023-08-23
ES2959504T3 (en) 2024-02-26
HRP20231021T1 (en) 2023-12-08
SV2016005266A (en) 2017-02-17
US10556961B2 (en) 2020-02-11
IL247403A0 (en) 2016-11-30
CA2940865A1 (en) 2015-09-03
EP3110440A4 (en) 2017-09-06
EP4272738A2 (en) 2023-11-08
KR20160126027A (en) 2016-11-01
KR102588587B1 (en) 2023-10-11
AU2024202215A1 (en) 2024-05-02
US11713355B2 (en) 2023-08-01
MX2016011187A (en) 2017-01-23
CA2940865C (en) 2022-08-30
WO2015130732A2 (en) 2015-09-03
MX388464B (en) 2025-03-20
GT201600171A (en) 2019-08-15
CR20160387A (en) 2016-11-07
CN106456731B (en) 2021-02-05
NZ723538A (en) 2023-08-25
WO2015130732A3 (en) 2016-03-17
US9732154B2 (en) 2017-08-15
SI3110440T1 (en) 2023-10-30
ES2959504T9 (en) 2024-05-29
DK3110440T3 (en) 2023-10-23
DOP2016000225A (en) 2017-03-31
DK3110440T5 (en) 2024-04-15
LT3110440T (en) 2023-10-25
PH12016501672A1 (en) 2016-10-03
AU2020250204A1 (en) 2020-11-05
US20170320961A1 (en) 2017-11-09
EP4272738A3 (en) 2024-02-14
FI3110440T3 (en) 2023-10-18
MX2021014888A (en) 2022-01-24
US20200223936A1 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
ZA201708448B (en) Anti-cd38 antibodies for treatment of acute lymphoblastic leukemia
IL252568A0 (en) Anti-cd38 antibodies for treatment of acute myeloid leukemia
IL279627A (en) Method for the treatment of depression
ZA201703585B (en) Combination immunotherapy approach for treatment of cancer
PT3063173T (en) Specific anti-cd38 antibodies for treating human cancers
IL285077A (en) Compounds for treatment of cancer
PL3122358T3 (en) Combinations of fgfr- and cmet-inhibitors for the treatment of cancer
IL252716A0 (en) Anti-csf1r antibodies for treating pvns
EP3215148A4 (en) Methods for treatment of cognitive decline
SG11201607130RA (en) Combination method for treatment of cancer
IL248697A0 (en) Methods of purifying antibodies
GB201609314D0 (en) Methods of forming compounds
EP3180011A4 (en) Immunotherapy for the treatment of cancer
ZA201608307B (en) Process for the purification of l-alpha-glycerophosphorylcholine
ZA201606921B (en) Use of xanthophylls for the treatment of cancers
IL247443B (en) Process for the preparation of 5-fluorotryptophol
GB201412010D0 (en) Treatment of hypertransaminasemia
PT3310711T (en) Process for the preparation of sodiuim cyanide
HUP1400518A2 (en) Process for the preparation of tofacitinib
ZA201704589B (en) Compounds for the treatment of cancer
GB201417465D0 (en) Treatment of cancers